Skip to main
STXS

Stereotaxis Inc (STXS) Stock Forecast & Price Target

Stereotaxis Inc (STXS) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Stereotaxis is a medical device company with a strong focus on robotic technologies for use in interventional procedures. Despite lower-than-expected revenue in the first quarter, the company is working to address headwinds and remains confident in its goal to reach production of 500 magnetic catheters per month by year-end. The company also has a strong sales pipeline and expects to see revenue growth in the back-half of the year, leading to a positive outlook for the stock.

Bears say

Stereotaxis is facing several headwinds, including slow adoption of new technologies by health care providers, potential collaboration risks with other manufacturers, and long sales and installation cycles that may cause fluctuations in quarterly results. In addition, the company may face operational and cash flow challenges, as well as potential delays or limitations in hospital purchases of their robotic systems. Despite these challenges, Stereotaxis has recently achieved several regulatory approvals and is making progress on increasing their production capacity, which could drive future revenue growth. However, we remain cautious on the company's near-term outlook and reiterate a negative view on the stock.

Stereotaxis Inc (STXS) has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Stereotaxis Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Stereotaxis Inc (STXS) Forecast

Analysts have given Stereotaxis Inc (STXS) a Buy based on their latest research and market trends.

According to 4 analysts, Stereotaxis Inc (STXS) has a Buy consensus rating as of Sep 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $3.38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $3.38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Stereotaxis Inc (STXS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.